Skip to main content

Closed

RPRX: Royalty Pharma plc Stock Analysis | finqOS

Healthcare · Medical - Pharmaceuticals

Loading chart data...

Current StateBalance holding

The verdict

Good business

Mixed

Revenue growth-3.9% / yr

Operating margin67.9%

ROIC8.4%

Financially safe

Strong

Debt / equity1.30×

Interest coverage4.9×

Current ratio2.66×

Valuation

Unrated

P/E ratio23.7×

Dividend yield1.6%

Royalty Pharma plc

RPRXNASDAQ·USD·Closed

Royalty Pharma plc

RPRXNASDAQ·USD·Closed

$58.43

−1.00%

$58.43

−$0.59 (1.00%)

52W Range

92thpctl

Volume

0.59×avg

Mkt Cap

25.13BUSD

P/E

23.7TTM

Div Yield

1.56%ann

52W Range

92thpctl

Volume

0.59×avg

Market Cap

25.13BUSD

P/E Ratio

23.7TTM

Div Yield

1.56%ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings